<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PALONOSETRON</span><br/>(pal-o-no'si-tron)<br/><span class="topboxtradename">Aloxi<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span>; <span class="classification">5-ht<sub>3</sub> antagonist</span><br/><b>Prototype: </b>Ondansetron<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mg/5 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Selectively blocks serotonin 5-HT<sub>3</sub> receptors found centrally in the chemoreceptor trigger zone (CTZ) in the hypothalamus, and peripherally at vagal nerve endings
         in the intestines.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents acute chemotherapy-induced nausea and vomiting associated with initial and repeat courses of moderately or highly
         emetogenic chemotherapy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to palonosetron; safety in patients &gt;65 and children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of Chemotherapy-Induced Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.25 mg infused over 30 sec 30 min prior to chemotherapy; do not repeat for at least 7 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Do not dilute and do not mix with other drugs.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 30 sec. Flush IV line with NS before and after administration.  
               </p>
</td>
</tr>
</table>
<p><span class="routemethod">INCOMPATIBILITIES</span> Do not mix with other drugs. 
      </p>
<ul>
<li>Store at room temperature of 15°30° C (59°86° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, anxiety, dizziness. <span class="typehead">GI:</span> Constipation, diarrhea, abdominal pain. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May prolong QTc interval; use cautiously with <b>amiodarone,</b>
<b>amoxapine,</b>
<b>bretylium,</b>
<b>dofetilide,</b>
<b>disopyramide,</b>
<b>epinephrine,</b>
<b>ibutilide,</b>
<b>maprotiline,</b>
<b>procainamide,</b>
<b>quinidine,</b>
<b>sotalol,</b>
<span class="classification">tricyclic antidepressants</span>, <span class="classification">phenothiazines</span>, <b>haloperidol,</b>
<b>pimozide,</b>
<b>risperidone,</b>
<b>sertindole,</b>
<b>ziprasidone,</b>
<b>arsenic trioxide,</b>
<b>bepridil,</b>
<b>clarithromycin,</b>
<b>cyclobenzaprine,</b>
<b>dolasetron,</b>
<b>droperidol,</b>
<b>erythromycin,</b>
<b>flecainide,</b>
<b>halofantrine,</b>
<b>halothane,</b>
<b>pentamidine,</b>
<b>probucol,</b>
<b>troleandomycin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Metabolized in liver by CYP2D6. <span class="typehead">Elimination:</span> Primarily renal. <span class="typehead">Half-Life:</span> 40 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely cardiac status especially in those taking diuretics or otherwise at risk for hypokalemia or hypomagnesemia,
            with congenital QT syndrome, or patients taking antiarrhythmic or other drugs that lead to QT prolongation.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following: difficulty breathing, wheezing, or shortness of breath; palpitations or chest tightness;
            skin rash or itching; swelling of the face, tongue, throat, hands, or feet.
         </li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>